Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Guijarro

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Nature|December 10, 2025
Fasting boosts breast cancer therapy efficacy via glucocorticoid activationNuno Padrão, Tesa M Severson, Sebastian Gregoricchio, et al.
European Urology Open Science|April 30, 2026
PSA Response as a Prognostic Factor of Overall Survival in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Real-world EvidenceAna Guijarro, Estíbaliz Jiménez, Antoni Vilaseca, et al.
Cancers|August 27, 2021
Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active TreatmentFrancesca Valdemarin, Irene Caffa, Angelica Persia, et al.
BJU International|April 6, 2026
Digital Uromonitor® outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urológico Español de Tratamiento Oncológico Group' (EVALUATION-CUETO) studyJose Rubio-Briones, Félix Guerrero Ramos, Asier Mercadé Sánchez, et al.
European Urology Open Science|October 30, 2024
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world DatabaseMario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, et al.
The Prostate|September 4, 2025
Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With ApalutamideChristian Andrés Martínez Osorio, Raquel Sopeña Sutil, Antoni Vilaseca Cabo, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Nature|December 10, 2025
Fasting boosts breast cancer therapy efficacy via glucocorticoid activationNuno Padrão, Tesa M Severson, Sebastian Gregoricchio, et al.
European Urology Open Science|April 30, 2026
PSA Response as a Prognostic Factor of Overall Survival in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Real-world EvidenceAna Guijarro, Estíbaliz Jiménez, Antoni Vilaseca, et al.
Cancers|August 27, 2021
Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active TreatmentFrancesca Valdemarin, Irene Caffa, Angelica Persia, et al.
BJU International|April 6, 2026
Digital Uromonitor® outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urológico Español de Tratamiento Oncológico Group' (EVALUATION-CUETO) studyJose Rubio-Briones, Félix Guerrero Ramos, Asier Mercadé Sánchez, et al.
European Urology Open Science|October 30, 2024
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world DatabaseMario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, et al.
The Prostate|September 4, 2025
Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With ApalutamideChristian Andrés Martínez Osorio, Raquel Sopeña Sutil, Antoni Vilaseca Cabo, et al.
Pageof 6